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28 
Synopsis 29 
Aims: To develop a population pharmacokinetic model of vancomycin in adult 30 
patients; to use this model to develop dosage guidelines targeting vancomycin trough 31 
concentrations of 10 – 15 mg/L and to evaluate the performance of these new 32 
guidelines. 33 
Methods: All data analyses were performed using NONMEM®.  A population 34 
pharmacokinetic model was first developed from vancomycin dosage and 35 
concentration data collected during routine TDM in 398 patients, then new 36 
vancomycin dosage guidelines were devised by using the model to predict 37 
vancomycin trough concentrations in a simulated dataset.  Individual estimates of CL 38 
and V1 were then obtained in an independent group of 100 patients using the 39 
population model and the POSTHOC option.  These individual estimates were used 40 
to predict vancomycin trough concentrations and steady state AUC24/MIC ratios using 41 
the current and new dosage guidelines.   42 
Results: The population analysis found that the vancomycin data were best 43 
described using a bi-exponential elimination model with a typical CL of 3.0 L/h that 44 
changed by 15.4% for every 10 mL/min difference from a CLCR of 66 mL/min.  Vss 45 
was 1.4 L/kg.  The proposed dosage guidelines were predicted to achieve 55% of 46 
vancomycin troughs within 10 – 15 mg/L and 71% within 10 – 20 mg/L, which is 47 
significantly higher than current guidelines (19% and 22% respectively).  The 48 
proportion of AUC24/MIC ratios above 400 was also higher; 87% compared to 58%. 49 
Discussion: New vancomycin dosage guidelines have been developed that achieve 50 
trough concentrations of 10 – 15 mg/L earlier and more consistently than current 51 
guidelines.   52 
244 words 53 
 54 
55 
INTRODUCTION 56 
 With the rapid increase in the incidence of methicillin-resistant 57 
Staphylococcus aureus (MRSA) infection and concerns about the clinical 58 
consequences of underdosing, achieving target concentrations of vancomycin 59 
efficiently has become increasingly important.  Traditionally, “peak” and “trough” 60 
concentrations were measured and the focus was on preventing toxicity by avoiding 61 
what were perceived to be excessive troughs (>10 mg/L).1   More recently, evidence 62 
that trough concentrations of 5 – 10 mg/L might be insufficient to achieve adequate 63 
tissue penetration and kill rates for more resistant species has prompted laboratories 64 
to recommend a variety of higher target values, up to and exceeding 15 mg/L.2   65 
These changes reflect current British National Formulary (BNF) recommendations of 66 
10 – 15 mg/L and 15 – 20 mg/L for more resistant strains.3   Similar targets have also 67 
been suggested for pneumonia4 and meningitis,5 while continuous infusions of 68 
vancomycin which target average steady state concentrations of 15 – 25 mg/L, have 69 
been advocated for critically ill patients.6   70 
Further support for using higher target concentrations of vancomycin is based 71 
on observations that nephrotoxicity is rare with the current formulation,7 although 72 
there is some evidence of an increased risk of nephrotoxicity with co-administration 73 
of other nephrotoxic agents, prolonged therapy and concentrations above 10 mg/L.8,9 74 
More recently, nephrotoxicity has been associated with vancomycin doses above 4 75 
grams per day,10  trough concentrations above 15 mg/L11,12  and average steady 76 
state concentrations above 28 mg/L.13    77 
Despite the current support for using more aggressive vancomycin therapy, a 78 
recent review revealed that none of the laboratories surveyed in Scotland had made 79 
changes to their hospital dosing recommendations.2  Furthermore, most established 80 
guidelines and nomograms quote only a standard dosage regimen3 or aim for target 81 
concentrations that are generally lower than currently recommended.14-17  This is 82 
reflected within Glasgow, where vancomycin is currently prescribed using dosage 83 
guidelines that were developed to achieve trough concentrations of 5 – 10 mg/L, 84 
although current laboratory practice favours BNF recommendations.3 These 85 
observations prompted the need for new dosage guidelines that could achieve these 86 
higher targets.   87 
The aims of this study were to develop a population pharmacokinetic model to 88 
describe the handling of vancomycin in adult patients from data collected during their 89 
routine clinical care, to use the model to develop dosage guidelines aimed at 90 
achieving higher trough concentrations and to evaluate the performance of these 91 
new guidelines using data collected from an independent group of patients. 92 
  93 
METHODS 94 
Study approval 95 
All data collected for this study were obtained during patients’ routine clinical 96 
care and the population analysis was defined as audit by the West Ethics Committee 97 
of the North Division of NHS Greater Glasgow (approval number 99/111, letter dated 98 
16 June 1999).  The data collection conducted at Southmead Hospital, Bristol was 99 
also designated as audit. 100 
 101 
Patients and data collection 102 
Data for population pharmacokinetic model development were collected 103 
retrospectively from routine therapeutic drug monitoring (TDM) files of patients who 104 
were treated with intravenous (iv) vancomycin therapy between May 1991 and July 105 
2004 at the Western Infirmary, Glasgow and Gartnavel General Hospital, Glasgow 106 
and prospectively from patients treated with vancomycin in Southmead Hospital, 107 
Bristol (1999 to 2002).  Data from 102 of the 398 patients who were included in this 108 
population model dataset had been included in a previous population modelling 109 
study.18   A second data set, which was used to evaluate the dosage guidelines, was 110 
compiled retrospectively from TDM files of 100 patients who were treated with iv 111 
vancomycin between November 2004 and June 2007 at the Western Infirmary, 112 
Glasgow.  For both data sets, patients aged 16 years or more and who had at least 113 
one vancomycin concentration measurement recorded, were eligible for inclusion.  114 
Patients in renal failure who were receiving renal replacement therapy and patients in 115 
whom dosage and/or sampling times were missing or not clear were excluded from 116 
the analysis.  117 
Information on vancomycin dosage amounts, exact dates and times, infusion 118 
length and patient demographic factors was extracted from routine TDM files that had 119 
been completed during each patient’s treatment.  Demographic data collected 120 
included patient age, total body weight (TBW), height and gender.  Lean body weight 121 
(LBW),19  LBW based on a semi-parametric calculation,20  ideal body weight (IBW),21 122 
and body surface area (BSA),22  were calculated from patient weight, height and 123 
gender.  Serial measurements of serum creatinine (SeCr) were recorded from TDM 124 
files and clinical chemistry electronic records.  SeCr measurements below the lower 125 
limit of the reference range (60 Pmol/L) were set to 60 Pmol/L as described 126 
previously.23   Creatinine clearance (CLCR) was calculated using the Cockcroft-Gault 127 
equation,24 the Jelliffe equation,25  the Salazar Corcoran equation,26  and the MDRD 128 
equation.27   Additionally, a CLCR estimate was obtained using LBW,19 and IBW,21 129 
instead of TBW in the Cockcroft-Gault equation.24  130 
Differences in demographic and clinical features between the population 131 
model development and evaluation patient groups were examined by calculating the 132 
95% confidence interval (CI) for the difference in proportion or by a Mann Whitney U 133 
test or Student’s t-test (as appropriate) with significance level set at p<0.05.   134 
 135 
Vancomycin assay 136 
Vancomycin drug concentrations were analysed by fluorescence polarization 137 
immunoassay at the Microbiology Departments of the Western Infirmary (TDx, Abbott 138 
Diagnostics, Chicago, USA) or Southmead Hospital (FLx, Abbott Diagnostics, 139 
Chicago, USA). The inter-assay coefficients of variation for the TDx were 4.3% at 140 
10.5 mg/L, 2.1% at 31 mg/L and 4.2% at 58 mg/L and for the FLx were 2.5% at 7.0 141 
mg/L, 1.9% at 35 mg/L and 2.0% at 75.0 mg/L.  The lower limit of quantification was 142 
2 mg/L for both analysers. 143 
 144 
Population pharmacokinetic analysis 145 
Population modelling was performed using NONMEM® (version 6, Globomax 146 
Inc.)28 with a G77 FORTRAN compiler.  Analysis and post processing were 147 
performed with the aid of the PsN toolkit,29 and Xpose (Version 4),30 programmed in 148 
the statistics package R.31  149 
Single and bi-exponential elimination models were compared and both 150 
untransformed and log-transformed vancomycin concentrations were analysed.  151 
Inter-individual variability in pharmacokinetic parameters was assumed to be log-152 
linear.  Residual error on concentration was described by a combined error model.  153 
Covariance between inter-individual variabilities in drug CL and V was examined.  All 154 
modelling was performed using First Order Conditional Estimation with interaction. 155 
Clinical factors investigated for an influence on the pharmacokinetics of 156 
vancomycin were: gender; age; TBW; LBW; IBW; BSA; height; day of therapy; SeCr 157 
and all CLCR estimates.  Potentially useful covariates were identified by GAM analysis 158 
and scatter plots and were then introduced sequentially into the population model.  159 
Models were compared visually with a range of plots and statistically using a 160 
likelihood ratio test on the differences in the objective function value (OFV) with 161 
significance set at p<0.005.  Changes in inter-individual variability and residual 162 
random error were also examined. 163 
Uncertainty in the final population model parameter estimates was assessed 164 
using a bootstrap method.32   In brief, this involves repeated random sampling, with 165 
replacement, of the original data set to produce another data set of the same size but 166 
with a different combination of subjects.  As the number of bootstrap samples 167 
approaches infinity, the sample standard deviations of the parameters approach the 168 
‘true’ (but unknown) standard deviations.  In this study, bootstrapping was performed 169 
with the assistance of the PsN toolkit.29  Mean parameter estimates obtained from 170 
250 bootstrap runs were compared to population mean values.   171 
 172 
Development of Dosage Guidelines 173 
A data set was created containing 110 simulated “patients” with a range of 174 
weights (40, 50, 60, 70, 80, 90, 100 or 120 kg) and CLCR estimates (15, 20, 25, 30, 175 
40, 50, 60, 70, 80, 90, 100, 110 or 125 mL/min) that spanned the typical patient 176 
population.  Draft dosage guidelines containing a range of loading and maintenance 177 
doses were then tested for their ability to achieve vancomycin trough concentrations 178 
of 10 – 15 mg/L during the first 4 days of therapy.  Dosage amounts were fixed to 179 
multiples of 250 mg and dosage intervals were limited to 12, 24 or 48 hours for 180 
practicality.  Each individual in the simulated dataset was assigned a vancomycin 181 
dosage history then trough concentrations were predicted by running NONMEM® 182 
with the population parameter values fixed at the final model estimates.  These 183 
predicted troughs were compared with the target range of 10 – 15 mg/L.  The draft 184 
guidelines were then amended for simulated patients whose weight and/or CLCR 185 
combinations resulted in vancomycin trough predictions outside the desired range.  186 
This process was repeated until final dosing guidelines were created that consistently 187 
achieved the target concentrations in the simulated patients. 188 
 189 
Evaluation of New Dosage Guidelines 190 
A data file containing all clinical, dosage and concentration data recorded for 191 
patients in the evaluation data set was created.  Individual estimates of vancomycin 192 
pharmacokinetic parameters were then obtained for each patient by MAP Bayesian 193 
analysis of their data using the final population model and the POSTHOC option in 194 
NONMEM®.  These empirical Bayes’ estimates were used to predict the trough 195 
concentrations that would have been expected during the first 4 days of therapy if 196 
each patient had been treated according to the current and the new dosage 197 
guidelines.  The proportions of concentrations within different ranges during the first 4 198 
days of therapy were compared by determining the 95% confidence intervals of their 199 
differences with correction for multiple comparisons.  Area under the concentration –200 
time curve for a 24 hour period at steady state (AUC24) was calculated from daily 201 
dose amount/CL and average steady state concentration (Css) from dose rate/CL. 202 
 203 
RESULTS 204 
Patients and data collection 205 
Data were collected from 398 patients for population model building (including 206 
99 patients from Bristol) and a further 100 patients for evaluation of the new dosage 207 
guidelines.  Demographic, clinical, dosage and concentration data from both groups 208 
are summarised in Table 1.  The population model data set comprised 1557 209 
vancomycin concentration measurements and the evaluation data set 171 210 
measurements. The median measured vancomycin concentration was 12.1 mg/L in 211 
both data sets.  The majority of samples, 64% and 62% respectively, were drawn at 212 
least 10 hours after the start of the infusion.  There were no significant differences 213 
between the population model building and evaluation datasets in terms of patients’ 214 
initial SeCr values, initial vancomycin dose, vancomycin concentration values or the 215 
length of time after the start of infusion that vancomycin concentrations were 216 
measured.  However, patients in the evaluation group were more likely to be female, 217 
to be older, to weigh less and to have lower CLCR estimates (Table 1).   218 
 219 
Population modelling 220 
The vancomycin data were best described by a bi-exponential elimination 221 
model and results were similar with non-transformed and log-transformed 222 
vancomycin concentration data.  The final covariate model included CLCR estimated 223 
using the Cockcroft-Gault equation based on TBW as the only factor affecting CL; 224 
TBW influenced both the volume of the central (V1) and peripheral compartments 225 
(V2).  Inclusion of CLCR reduced inter-individual variability on CL from 53% to 27% 226 
and the model OFV by 679 points and the addition of TBW reduced inter-individual 227 
variability on V1 from 26% to 15% and the model OFV by a further 34 points. 228 
Pharmacokinetic parameter estimates from the final population model are 229 
presented in Table 2.  The parameter values from the final model obtained from 230 
application of bootstrap analysis were similar to the final model developed using the 231 
398 patients, with no parameter difference greater than 10%.  A plot of model-232 
predicted versus observed concentrations for the final model based on population 233 
parameter estimates and individual parameter estimates is shown in Figures 1a and 234 
1b respectively.  Examination of plots of conditional weighted residuals (CWRES) 235 
versus time after dose confirmed the appropriateness of the bi-exponential 236 
elimination model.     237 
 238 
Development and evaluation of dosage guidelines 239 
Table 3 shows the guidelines currently in use within North Glasgow (target 240 
trough 5 – 10 mg/L) and Tables 4 and 5 the revised guidelines (target trough 10 – 15 241 
mg/L).  Although the doses are generally similar, the new guidelines included a 242 
loading dose and tended to recommend higher doses or shorter dosage intervals (i.e. 243 
the same daily dose but split and given 12 hourly rather than 24 hourly).   244 
POSTHOC analysis of the evaluation data set encountered problems with 245 
non-physiological values when all parameters were estimated therefore only CL and 246 
V1 were estimated; V2 and intercompartmental clearance (Q) were fixed at 247 
population values. Using these individual CL and V1 estimates, the predicted trough 248 
concentrations in the validation data set over the first 4 days of therapy were 249 
consistently higher at each time point with the new guidelines (Figure 2a) compared 250 
to the old guidelines (Figure 2b).  Mean (SD) predicted trough concentrations during 251 
this period were also significantly higher with the new guidelines 12.2 (3.4) mg/L, (n = 252 
688) compared to 7.9 (3.3) mg/L with the old guidelines (n = 514).  Differences in the 253 
number of samples reflect more 12 hourly dosing with the new guidelines.  254 
Furthermore, Table 6 shows that the proportions of concentrations within the ranges 255 
10 – 15 mg/L, 15 – 20 mg/L and >20 mg/L were also higher.  Overall, within the first 4 256 
days of therapy, 55% of vancomycin trough concentrations were predicted to be 257 
within 10 – 15 mg/L with the new dosage guidelines compared with only 19% with the 258 
current dosage guidelines.  The percentages within the range 10 – 20 mg/L were 259 
even higher (71% compared to 22%).  Predicted average Css concentration and 260 
AUC24 in the validation data set were also higher with the new guidelines.  Mean (SD) 261 
estimates of AUC24 were 520 (124) mg.h/L and 436 (104) mg.h/L and mean (SD) Css 262 
estimates were 21.7 (5.2) mg/L and 18.2 (4.3) mg/L respectively. Assuming an MIC 263 
of 1 mg/L, 87% of patients were predicted to have an AUC24/MIC ratio above 400 and 264 
only 4% would be below 350 if the new guidelines were followed, compared to 58% 265 
and 24%, respectively, with the current guidelines.  266 
 267 
DISCUSSION 268 
 This study used data collected during routine TDM to determine population 269 
estimates of vancomycin pharmacokinetic parameters, develop new dosage 270 
guidelines and evaluate these new guidelines prospectively. 271 
 Some of the data that were included in the present population analysis had 272 
been analysed previously in an investigation of vancomycin pharmacokinetics in 102 273 
cardiothoracic surgery patients with unstable renal function.18  This previous study 274 
found that data from such patients could be described adequately if serial  275 
measurements of creatinine concentration, which indicated renal function changes, 276 
were available. Although a mono-exponential elimination model proved adequate in 277 
the earlier study, the current analysis found that the data were better described using 278 
a two-compartment model.  The typical estimate of CL was 3 L/h in both analyses but 279 
the influence of CLCR was slightly different; the previous study identified a 20.5% 280 
change in vancomycin CL with every 10 mL/min change in CLCR from 66 mL/min 281 
compared to only 15.4% in the current analysis.  The Cockcroft Gault equation24 282 
based on TBW provided the best fit of the data overall.  Other pharmacokinetic 283 
studies have found similar relationships between vancomycin CL and CLCR.  Based 284 
on a CLCR of 66 mL/min, CL estimates identified in these earlier studies were typically 285 
around 3.0 L/h and ranged from 2.9 to 4.3 L/h.15, 33-37  286 
The volume of distribution of vancomycin is generally reported as 0.5 – 0.98 287 
L/kg with an average around 0.7 L/kg14,15,33,34,37, which is similar to the estimate of V1 288 
(0.7 L/kg) identified in the present study.  Although volume of distribution at steady 289 
state (Vss) was higher at 1.4 L/kg, both Llopis-Salvia et al36 and Fernández de Gatta 290 
Garcia et al38 reported even higher estimates (1.7 L/kg TBW) in their population 291 
analyses of vancomycin pharmacokinetics.  It is possible that differences in the 292 
duration of therapy, the pharmacokinetic model used to analyse the data and the 293 
clinical characteristics of the patients included in each study may have contributed to 294 
these observations.   295 
 For both CL and V, a range of weight measurements were tested in the 296 
population analysis, and although 19% of patients were clinically obese (Body Mass 297 
Index >30 kg/m2) no clear improvement in the fit of the population model was 298 
identified if TBW was replaced by LBW or IBW.  These findings are consistent with 299 
other studies.  Although conflicting results have been reported on the influence of 300 
obesity on vancomycin CL and V, TBW is usually recommended for dosage 301 
adjustment39-42 and has practical advantages when applied in a routine clinical 302 
environment.  However, particular care is required when prescribing for patients who 303 
are obese or underweight and close monitoring of vancomycin concentrations is 304 
advised to ensure that dosage regimens are appropriate. 305 
 The current BNF dosage recommendation for iv pulsed infusion vancomycin 306 
has recently been changed to 1000 – 1500 mg twice daily reduced to 500 mg twice 307 
daily or 1000 mg daily in patients over 65 years of age3.  Although these doses are 308 
higher than previously recommended, it is not clear what trough concentrations will 309 
be obtained with these dosage regimens and there is no guidance on how to adjust 310 
for renal impairment.  Other published dosage guidelines aim for troughs of 5 – 10 311 
mg/L,15,17 5 – 20 mg/L16  or an average steady state concentration of 15 mg/L.14 312 
However, to achieve trough concentrations above 10 mg/L, daily doses greater than 313 
2000 mg are usually required for patients with normal renal function, particularly if 314 
they are critically ill.38,42,43   The present study demonstrated that the new guidelines 315 
should achieve vancomycin trough concentrations of 10 – 15 mg/L earlier and more 316 
consistently than current dosage guidelines.  Other indicators of vancomycin efficacy 317 
have also been investigated. Moise-Broder et al44 reported that clinical outcome was 318 
significantly better if the AUC24/MIC ratio was greater than 400 in patients with S. 319 
aureus lower respiratory tract infections and this target ratio has recently been 320 
recommended in an American consensus review.42  In the present study, 87% of 321 
patients were predicted to achieve satisfactory AUC24/MIC ratio ratios if the new 322 
guidelines were followed.  Low AUC24/MIC ratios typically occurred when the 323 
individual estimate of CL was  higher than predicted from CLCR.   Much higher doses 324 
or an alternative antibiotic would be required if the MIC was 2 mg/L since only 2% of 325 
patients would be likely to achieve an AUC24/MIC ratio above 400.  These difficulties 326 
prompted the authors of the American consensus review to question the value of 327 
vancomycin in the treatment of MRSA infections if the strain has an MIC above 1 328 
mg/L.42    329 
The present study has confirmed the importance of giving a loading dose 330 
when starting vancomycin therapy, especially in patients with renal impairment, in 331 
whom accumulation to steady state will take longer.  Although the need for a loading 332 
dose has been recognised for many years,15,45 and has recently been highlighted 333 
again,42 loading doses are absent from the BNF guidelines3 and are not often used in 334 
routine clinical practice.   335 
Figure 2a demonstrates that the new dosage guidelines lead to a greater risk 336 
of vancomycin trough concentrations accumulating above 15 mg/L, especially after 337 
day 3 of therapy.  This emphasises the need for monitoring vancomycin 338 
concentrations within the first 3 days to avoid excessive accumulation and potential 339 
for toxicity.9   However, troughs of 15 – 20 mg/L may also simply reflect the flatter 340 
profile that the new guidelines aim to achieve.  An extension of this principle would 341 
be to administer vancomycin by continuous infusion; an alternative approach that is 342 
increasingly being used in routine clinical practice since it is easier to monitor and 343 
adjust doses.  The pulsed infusion doses recommended in the new guidelines 344 
presented here should achieve average steady state concentrations of around 22 345 
mg/L and are therefore compatible with the continuous infusion target concentrations 346 
of 15 – 25 mg/L that are commonly advocated6 and well below the 28 mg/L cut-off 347 
identified by Ingram et al13 as being associated with an increased risk of toxicity.  348 
Consequently, a trough of 15 – 20 mg/L does not necessarily indicate a problem; it 349 
may simply reflect a flatter profile in a patient with poor renal function.  Dosage 350 
intervals of 8 hours offer an alternative administration method in cases where the 351 
required daily dose is particularly high or could easily be divided into 3, for example, 352 
1000 mg 8 hourly rather than 1500 mg twice daily or 500 mg 8 hourly rather than 750 353 
mg twice daily.  Six hourly administration of half the 12 hourly dose would also be 354 
feasible but may be difficult to manage on a busy ward.   Both options would achieve 355 
higher trough concentrations and lower peaks but the same overall exposure 356 
(AUC24).   357 
 In conclusion, this study has developed new, iv pulsed infusion dosage 358 
guidelines for vancomycin following a population analysis of routine vancomycin 359 
concentration data.  The new guidelines are based on practical doses that are easy 360 
to prepare and administer, and reflect current vancomycin target concentrations.  A 361 
preliminary evaluation of the guidelines using data collected from a separate group of 362 
patients indicated that 55% of trough concentrations should be within 10 – 15 mg/L 363 
and 71% within 10 – 20 mg/L over the first 4 days of therapy and that satisfactory 364 
AUC24/MIC ratios should be achieved in 87% of patients, assuming an MIC of 1 365 
mg/L. However, wide variability in the handling of vancomycin between and within 366 
patients indicates that monitoring of concentrations is required to ensure that dosage 367 
regimens are appropriate for individual patients.    368 
 369 
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46. FIGURE LEGENDS 510 
 511 
Figure 1 512 
Plots of model-predicted versus observed concentrations for the final model based 513 
on a) population parameter estimates and b) individual parameter estimates. 514 
 515 
 516 
Figure 2  517 
Box and whisker plots of the distributions of vancomycin trough concentrations over 518 
the first 4 days of therapy predicted from a) the new dosage guidelines and b) the 519 
current dosage guidelines using CL and V1 estimates derived from routine data 520 
collected from 100 patients. 521 
 522 
523 
Table 1: Patient demographic and pharmacokinetic features of the model 524 
development and evaluation datasets.  Results are presented as number, or 525 
median (range). 526 
 527 
 Population model 
building dataset 
Dosage guideline 
evaluation dataset 
Statistical 
comparison
Demographic data 
 
   
Number of patients 398 100  
Males (%) 63 
 
50 
 
p = 0.019 
 
Age (years) 66 (16 – 97) 71 (22 – 91) p < 0.001 
Weight (kg) 72 (40 – 159) 65 (35 – 130) p < 0.001 
Initial SeCr (Pmol/L) 98 (30 – 573) 94 (55 – 353) NS 
Initial CLCR (mL/min) 64 (12 – 216) 50 (12 – 148) p = 0.003 
Pharmacokinetic data    
Number of samples 1557 171  
Initial dose (mg) 1000 (500 – 1750) 1000 (500 – 1500) NS 
Concentration (mg/L) 12.1 (2.0 – 49.2) 12.1 (2.0 – 29.2) NS 
Samples per patient 3 (1 – 19) 2 (1 – 5) p < 0.001 
Time after start of 
infusion (hrs) 11.9 (1.1 – 92.3) 12.4 (0.3 – 57.3) NS 
Follow-up period (days) 4.9 (0.5 – 44.4) 2.5 (0.2 –  9.3) p < 0.001 
 528 
529 
Table 2: Population parameter estimates based on the final population model.  530 
 531 
Population model Final 
estimates 
RSE
% 
Bootstrap 
estimates 
95% CI 
CL (L/h) 2.99 1.9 2.98 (2.85 - 3.13) 
TCRCL 0.0154 4.3 0.0154 (0.0144 - 0.0165) 
V1 (L/kg)   0.675 1.8 0.676 (0.637 - 0.713) 
V2 (L/kg) 0.732 0.7 0.775 (0.543 - 1.090) 
Q (h-1)  2.28 23.7 2.25 (1.68 - 2.90) 
KCL (%) 27 14 27 (24 - 31) 
KV1 (%) 15 40 15 (8 - 21) 
KV2 (%) 130 20 125 (88 - 150) 
KQ (%) 49 29 54 (34 - 81) 
Additive error  (mg/L) 1.6 7.7 1.6 (1.3 - 1.8) 
Proportional error (%) 15 7 15 (12 - 17) 
 532 
Key: CL = typical estimate of clearance for a CLCR of 66 mL/min, TCRCL = proportional 533 
change in CL with CLCR (calculated using TBW and Cockcroft-Gault equation24), Q 534 
intercompartmental CL, K = inter individual variability expressed as a percentage, 535 
RSE = relative standard error expressed as a percentage coefficient of variation, 536 
#(mL/min) 537 
538 
Table 3: Current vancomycin dosage guidelines.  539 
 540 
CLCR (mL/min) Weight <60 kg Weight >60 kg 
< 20 1000 mg then sample after 24 hrs 1000 mg then sample after 24 hrs 
20 - 29 1000 mg 48 hourly 1000 mg 48 hourly 
30 - 49 750 mg 24 hourly 750 mg 24 hourly 
50 - 59 1000 mg 24 hourly 1000 mg 24 hourly 
60 - 69 500 mg 12 hourly 1000 mg 24 hourly 
70 - 79 750 mg 12 hourly 750 mg 12 hourly 
80 - 100 750 mg 12 hourly 1000 mg 12 hourly 
> 100 1250 mg 12 hourly 1250 mg 12 hourly 
 541 
Key: CLCR estimate based on the Cockcroft-Gault equation24 542 
543 
Table 4: New vancomycin loading dose guidelines based on the final 544 
population model. 545 
 546 
Loading Dose 547 
Weight < 60 kg 60 – 90 kg >90 kg 
Loading dose  1000 mg 1500 mg 2000 mg 
 548 
 549 
 550 
 551 
Table 5: New vancomycin maintenance dose guidelines based on the final 552 
population model. 553 
 554 
Maintenance Dose  555 
CLCR (mL/min) Dose (mg) Interval (hrs) 
< 20 500 mg 48 hours 
20 - 29 500 mg 24 hours 
30 - 39 750 mg 24 hours 
40 - 54 500 mg 12 hours 
55 - 74 750 mg 12 hours 
75 - 89 1000 mg 12 hours 
90 - 110 1250 mg 12 hours 
>110 1500 mg 12 hours 
 556 
Key: CLCR estimate based on the Cockcroft-Gault equation24. N.B. Higher troughs 557 
and lower peaks would be achieved by splitting the total daily dose into 3 or 4 equal 558 
portions, for example, 1000 mg 8 hourly instead of 1500 mg 12 hourly or 500 mg 6 559 
hourly instead of 1000 mg 12 hourly. 560 
Table 6: Proportions (%) of predicted vancomycin trough concentrations within 561 
different ranges during the first 4 days of therapy. 562 
 563 
Predicted 
concentration 
range 
Current 
guidelines (n = 
514 ) 
New guidelines 
(n = 688) 
Difference in 
proportion 
99% CI of the 
difference 
< 10 mg/L 0.77 (77%) 0.26 (26%) -0.51 -0.44 to  -0.57 
10 – 15 mg/L 0.19 (19%) 0.55 (55%) 0.36 0.30 to 0.43 
15 – 20 mg/L 0.03 (3%) 0.16 (16%) 0.13 0.09 to 0.17 
> 20 mg/L 0.00 (0%) 0.03 (3%) 0.03 0.01 to 0.04 
 564 
Key: n = the number of predicted trough concentrations during the first 4 days in the 565 
100 evaluation patients.   566 
567 
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Figure 2 b 
